ESCMID: Update of the Treatment Guidance Document for Clostridium difficile Infection
The previous European Society of Clinical Microbiology and Infection (ESCMID) guidance document, which has been applied widely in clinical practice, dates from 2009. Meanwhile, new treatments for Clostridium difficile infection (CDI) have been developed and limitations of the currently recommended treatment options of CDI are considered. As the current ESCMID treatment guidance document is already implemented in clinical practice, an update of this widely applied guidance document is essential to further improve uniformity of national hospital infection treatment policies for CDI in Europe. In particular, after the recent development of new alternative drugs for the treatment of CDI (e.g. fidaxomicin) in the USA and Europe, there has been an increasing need for an update on the comparative effectiveness of the currently available antibiotic agents in the treatment of CDI, thereby providing evidence-based recommendations on this issue.